CD274 Human, Sf9
Sf9, Baculovirus cells.
CD274 molecule, CD274 antigen, programmed cell death 1 ligand 1, PD-L1, PDCD1L1, PDCD1LG1, PDCD1 ligand 1, B7 homolog 1, B7H1.
Greater than 95% as determined by SDS-PAGE.
Description
CD274 Human Recombinant produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 462 amino acids (19-238a.a.) and having a molecular mass of 52.5kDa (Molecular size on SDS-PAGE will appear at approximately 50-70kDa). CD274 is expressed with a 239 amino acids hIgG-His tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
CD274 molecule, CD274 antigen, programmed cell death 1 ligand 1, PD-L1, PDCD1L1, PDCD1LG1, PDCD1 ligand 1, B7 homolog 1, B7H1.
Sf9, Baculovirus cells.
ADLFTVTVPK DLYVVEYGSN MTIECKFPVE KQLDLAALIV YWEMEDKNII QFVHGEEDLK VQHSSYRQRA RLLKDQLSLG NAALQITDVK LQDAGVYRCM ISYGGADYKR ITVKVNAPYN KINQRILVVD PVTSEHELTC QAEGYPKAEV IWTSSDHQVL SGKTTTTNSK REEKLFNVTS TLRINTTTNE IFYCTFRRLD PEENHTAELV IPELPLAHPP NERLEPKSCD KTHTCPPCPA PELLGGPSVF LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGKHHHH HH.
Product Science Overview
CD274 is a transmembrane protein that is expressed on the surface of various cell types, including tumor cells, immune cells, and other tissues . The human recombinant form of CD274 produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 462 amino acids, with a molecular mass of approximately 52.5 kDa . This recombinant protein is often used in research to study its function and interactions.
CD274 interacts with its receptor, programmed death 1 (PD-1), which is expressed on T-cells. This interaction inhibits T-cell function, allowing tumor cells to escape immune surveillance . By binding to PD-1, CD274 reduces the proliferation of T-cells, decreases cytokine production, and promotes the apoptosis of antigen-specific T-cells . This mechanism is crucial for maintaining immune tolerance and preventing autoimmunity, but it also enables tumors to evade the immune response.
The expression of CD274 is upregulated in various cancers, including solid tumors and hematologic malignancies . This upregulation is associated with poor prognosis and reduced overall survival in cancer patients. Targeting the CD274/PD-1 pathway with monoclonal antibodies has shown promising results in enhancing the antitumor immune response . These therapies, known as immune checkpoint inhibitors, have become a cornerstone in the treatment of several types of cancer.
The recombinant form of CD274 produced in Sf9 cells is widely used in research to study its biological functions and to develop therapeutic antibodies. Studies have shown that CD274 promotes the cell cycle entry of leukemia-initiating cells through the JNK/Cyclin D2 signaling pathway . This pathway is a potential therapeutic target for the treatment of leukemia and other cancers.
